biostudies-literatureSievilainen MHelsingin ja Uudenmaan SairaanhoitopiiriJane ja Aatos Erkon SäätiöHelsingin YliopistoSigrid Juséliuksen SäätiöMinerva FoundationCancer Foundation Finland srSuomen Hammaslääkäriseura ApolloniaSyöpäjärjestöt812822https://www.ebi.ac.uk/biostudies/studies/S-EPMC8963946biostudies-literatureUnknown13<h4>Background</h4>Immune checkpoint inhibitors (ICIs), primarily anti-PD-1, are currently used to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, only a minority of patients benefit from these costly therapies. Therefore, there is an unmet need to better understand the effect of ICIs on immune effector cells. This study aimed to investigate the effect of a PD-1 antibody and an IDO1 inhibitor on different lymphocyte populations (NK, CD4⁺, and CD8⁺ T cells) in term of migration, cytotoxicity, and cytokine release in the presence of HNSCC cells.<h4>Methods</h4>Using a microfluidic chip, we injected HSC-3 cells (an oral tongue squamous cell carcinoma cell line) embedded in a human tumor-derived matrix "myogel/fibrin" toFrontiers in immunologyIDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.PMC8963946210073Al-Samadi ASievilainen MSaavalainen JAdnan-Awad SSalo TfalseIDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.<h4>Background</h4>Immune checkpoint inhibitors (ICIs), primarily anti-PD-1, are currently used to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, only a minority of patients benefit from these costly therapies. Therefore, there is an unmet need to better understand the effect of ICIs on immune effector cells. This study aimed to investigate the effect of a PD-1 antibody and an IDO1 inhibitor on different lymphocyte populations (NK, CD4⁺, and CD8⁺ T cells) in term of migration, cytotoxicity, and cytokine release in the presence of HNSCC cells.<h4>Methods</h4>Using a microfluidic chip, we injected HSC-3 cells (an oral tongue squamous cell carcinoma cell line) embedded in a human tumor-derived matrix "myogel/fibrin" to2022-01-01T00:00:00Z20222026-05-31T03:14:54.896Z2024-11-05T18:22:27.279ZS-EPMC89639463535998010.3389/fimmu.2022.812822